# Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger

> **NCT02145000** · PHASE3 · COMPLETED · sponsor: **Epicentre** · enrollment: 6586 (actual)

## Conditions studied

- Severe Rotavirus Gastroenteritis

## Interventions

- **BIOLOGICAL:** Rotavirus vaccine (BRV-PV)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02145000
- **Lead sponsor:** Epicentre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-12
- **Final completion:** 2020-12-31
- **Target enrollment:** 6586 (ACTUAL)
- **Last updated:** 2023-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145000, "Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02145000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*